GlassScriptPhysician profile
Michael L Weinrauch
NPI 1992778856
$8,085.07
in general payments reported to CMS, 2019-2025
42 companies · $1,642 in 2025
The $1,642 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,391 · 2020: $640 · 2021: $754 · 2022: $1,147 · 2023: $1,264 · 2024: $1,246 · 2025: $1,642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,152.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,233.09 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $634.36 | 2019-2025 | Jardiance |
| Pfizer INC. | $600.41 | 2019-2025 | |
| Amarin Pharma, INC. | $546.34 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $542.67 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $474.95 | 2021-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $446.15 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $352.80 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $306.11 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $283.75 | 2019-2025 | Farxiga, Lokelma |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $281.45 | 2019-2025 | Lifevest |
| Novo Nordisk INC | $218.41 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Baxter Healthcare | $192.50 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor |
| Esperion Therapeutics, INC. | $189.74 | 2021-2025 | Nexletol |
| Edwards Lifesciences Corporation | $186.75 | 2020 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Weinrauch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.